Frazier Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,654,938
Closed -$10M 33
2021
Q4
$10M Buy
1,654,938
+803,300
+94% +$7.72M 0.77% 32
2021
Q3
$11.8M Buy
+851,638
New +$10.1M 0.95% 26

Other funds holding GRCL

Frazier Management's GRCL Position: Q1 2022 in Review

Frazier Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2022, closing a stake of 1,654,938 shares — an estimated $10M sold.

Frazier Management first reported a position in GRCL in Q3 2021 and held it in 2 quarters. The position peaked at $11.8M in Q3 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q1 2022.

  • Frazier Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 1,654,938 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2022, an estimated $10M.
  • Frazier Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2021 and held it in 2 quarters.
  • Frazier Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $11.8M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.